Maintenance Gemcitabine plus Paclitaxel Chemotherapy Offers Improved Outcomes in Metastatic Breast Cancer

Share this content:

(CHICAGO, IL) – Maintenance chemotherapy with the combination of gemcitabine and paclitaxel (GP) following clinical response to GP is associated with improved survival times among metastatic breast cancer patients without impairing patient quality of life, according to results of a Phase 3 clinical trial presented at the 2012 American Society of Clinical Oncology Annual Meeting.

The prospective, randomized, multicenter study was intended to clarify the optimal duration of chemotherapy for metastatic breast cancer, which remains controversial, said lead author Young-Hyuck Im, MD, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. The study also aimed to determine if GP is superior to observation in terms of progression-free survival (PFS) in responding patients with metastatic breast cancer after 6 cycles of GP as first-line treatment. The study was conducted at 10 cancer centers by the Korean Cancer Study Group between 2007 and 2010.

Metastatic breast cancer patients who achieved complete or partial response, or stable disease, after 6 cycles of GP chemotherapy (gemcitabine 1,250mg/m2 on Day 1 and 8, plus paclitaxel 175mg/m2 on Day 1 every 3 weeks) were randomly assigned either to a maintenance-until-progression arm or an observation arm

At a median follow-up period of 33 months, median PFS was significantly longer among 116 patients in the GP maintenance-arm than the 115 patients assigned to the observation control group, 12.0 vs. 8.3 months; HR 0.73 (95% CI: 0.55–0.97); P=0.031. From randomization, median PFS was 7.5 months in the maintenance arm vs. 3.8 months in the observation arm (adjusted HR 0.73 [95% CI: 0.55–0.96]; P=0.026). Median 6-month PFS rate was 59.7% in the GP maintenance arm vs. 36% in the observation arm (P=0.00023).

Although these data are preliminary, median overall survival (OS) was significantly prolonged among patients receiving maintenance therapy compared with those in the observation group, 36.8 vs. 28.0 months; HR 0.65 (95% CI: 0.42–0.99); P=0.048).

No impairment in quality of life was observed in the maintenance GP arm, Dr. Im said. He concluded by noting that maintenance GP chemotherapy after 6 cycles should be considered in patients with metastatic breast cancer who have negative hormone receptor tumors, visceral disease, high tumor burden, are aged 50 years or younger, or are premenopausal.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs